Stock Analiz

MapLight Therapeutics, Inc. MPLT

Biotechnology: Pharmaceutical Preparations · IPO 2025 · data as of November 13, 2026

$7.25Market cap $403M
Open the interactive analysis →

MapLight Therapeutics, Inc. (MPLT) is a healthcare company listed in the US with a market value of about $403M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -29%.

About MapLight Therapeutics

MapLight Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2025. It was profitable in 0 of the last 2 years in our data.

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B1.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-43.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-28.8%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 2 years

Fiscal year20252024
Revenue——
Net income-$161M-$78M
Free cash flow-$139M-$80M
EPS (diluted)$-18.56$-105.38
Net margin——
ROIC-28.8%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 13 analysts is $26.54, 266% above the current price; targets range from $13.00 to $43.00; the consensus rating is “none”; expected EPS is $-4.49 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does MapLight Therapeutics pay a dividend?

Not currently.

Is MapLight Therapeutics a good stock to buy?

We do not give buy or sell advice. MapLight Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.